Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Karin Ribi

Showing results (61-70 of 86) with videos related to

Pageof 9
Sort By:
Breast (Edinburgh, Scotland)|March 5, 2013
Adjuvant pegylated liposomal doxorubicin for older women with endocrine nonresponsive breast cancer who are NOT suitable for a "standard chemotherapy regimen": the CASA randomized trialDiana Crivellari, Kathryn P Gray, Silvia Dellapasqua, et al.
European Journal of Cancer (Oxford, England : 1990)|November 19, 2011
Outcome, quality of life and cognitive function of patients with brain metastases from non-small cell lung cancer treated with whole brain radiotherapy combined with gefitinib or temozolomide. A randomised phase II trial of the Swiss Group for Clinical Cancer Research (SAKK 70/03)Gianfranco A Pesce, Dirk Klingbiel, Karin Ribi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 8, 2023
Darolutamide Maintenance in Patients With Metastatic Castration-Resistant Prostate Cancer With Nonprogressive Disease After Taxane Treatment (SAKK 08/16)Silke Gillessen, Giuseppe Procopio, Stefanie Hayoz, et al.
JAMA Oncology|August 10, 2023
Pertuzumab Plus Trastuzumab With or Without Chemotherapy Followed by Emtansine in ERBB2-Positive Metastatic Breast Cancer: A Secondary Analysis of a Randomized Clinical TrialJens Huober, Patrik Weder, Karin Ribi, et al.
The Lancet. Oncology|June 21, 2015
Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trialsJürg Bernhard, Weixiu Luo, Karin Ribi, et al.
Lung Cancer (Amsterdam, Netherlands)|December 28, 2024
Immunotherapy or targeted therapy with or without stereotactic radiosurgery for patients with brain metastases from melanoma or non-small cell lung cancer - The ETOP 19-21 USZ-STRIKE studyMichael Weller, Emilie Le Rhun, Lydia Tsamtsouri, et al.
The Lancet. Oncology|November 6, 2015
Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma with or without hemithoracic radiotherapy (SAKK 17/04): a randomised, international, multicentre phase 2 trialRolf A Stahel, Oliver Riesterer, Alexandros Xyrafas, et al.
European Urology Oncology|January 11, 2022
A Phase 1/2 Single-arm Clinical Trial of Recombinant Bacillus Calmette-Guérin (BCG) VPM1002BC Immunotherapy in Non-muscle-invasive Bladder Cancer Recurrence After Conventional BCG Therapy: SAKK 06/14Cyrill A Rentsch, George N Thalmann, Ilaria Lucca, et al.
British Journal of Cancer|April 20, 2016
Adjuvant ovarian function suppression and cognitive function in women with breast cancerKelly-Anne Phillips, Meredith M Regan, Karin Ribi, et al.
Breast (Edinburgh, Scotland)|July 13, 2024
Factors influencing 5-year persistence to adjuvant endocrine therapy in young women with breast cancerEleonora Pagan, Monica Ruggeri, Nadia Bianco, et al.
Pageof 9

Showing results (61-70 of 86) with videos related to

Sort By:
Pageof 9
Breast (Edinburgh, Scotland)|March 5, 2013
Adjuvant pegylated liposomal doxorubicin for older women with endocrine nonresponsive breast cancer who are NOT suitable for a "standard chemotherapy regimen": the CASA randomized trialDiana Crivellari, Kathryn P Gray, Silvia Dellapasqua, et al.
European Journal of Cancer (Oxford, England : 1990)|November 19, 2011
Outcome, quality of life and cognitive function of patients with brain metastases from non-small cell lung cancer treated with whole brain radiotherapy combined with gefitinib or temozolomide. A randomised phase II trial of the Swiss Group for Clinical Cancer Research (SAKK 70/03)Gianfranco A Pesce, Dirk Klingbiel, Karin Ribi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 8, 2023
Darolutamide Maintenance in Patients With Metastatic Castration-Resistant Prostate Cancer With Nonprogressive Disease After Taxane Treatment (SAKK 08/16)Silke Gillessen, Giuseppe Procopio, Stefanie Hayoz, et al.
JAMA Oncology|August 10, 2023
Pertuzumab Plus Trastuzumab With or Without Chemotherapy Followed by Emtansine in ERBB2-Positive Metastatic Breast Cancer: A Secondary Analysis of a Randomized Clinical TrialJens Huober, Patrik Weder, Karin Ribi, et al.
The Lancet. Oncology|June 21, 2015
Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trialsJürg Bernhard, Weixiu Luo, Karin Ribi, et al.
Lung Cancer (Amsterdam, Netherlands)|December 28, 2024
Immunotherapy or targeted therapy with or without stereotactic radiosurgery for patients with brain metastases from melanoma or non-small cell lung cancer - The ETOP 19-21 USZ-STRIKE studyMichael Weller, Emilie Le Rhun, Lydia Tsamtsouri, et al.
The Lancet. Oncology|November 6, 2015
Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma with or without hemithoracic radiotherapy (SAKK 17/04): a randomised, international, multicentre phase 2 trialRolf A Stahel, Oliver Riesterer, Alexandros Xyrafas, et al.
European Urology Oncology|January 11, 2022
A Phase 1/2 Single-arm Clinical Trial of Recombinant Bacillus Calmette-Guérin (BCG) VPM1002BC Immunotherapy in Non-muscle-invasive Bladder Cancer Recurrence After Conventional BCG Therapy: SAKK 06/14Cyrill A Rentsch, George N Thalmann, Ilaria Lucca, et al.
British Journal of Cancer|April 20, 2016
Adjuvant ovarian function suppression and cognitive function in women with breast cancerKelly-Anne Phillips, Meredith M Regan, Karin Ribi, et al.
Breast (Edinburgh, Scotland)|July 13, 2024
Factors influencing 5-year persistence to adjuvant endocrine therapy in young women with breast cancerEleonora Pagan, Monica Ruggeri, Nadia Bianco, et al.
Pageof 9